My insurance denied Wegovy. Are compounded GLP-1s my best option?

Short answer: usually no — compounded GLP‑1s are generally not the best first choice. They carry safety, quality and legal risks and are rarely covered by insurance. You should first pursue appeals and manufacturer help and discuss safe, approved alternatives with your prescriber.

Why compounded GLP‑1s are risky

• Not FDA‑approved: potency, purity, sterility and expiration aren’t guaranteed the way they are for Wegovy/other branded drugs.
• Safety concerns: injectable compounding can introduce contamination or incorrect dosing — higher infection or adverse‑event risk.
• Legal/patent and coverage issues: insurers won’t cover compounded versions; manufacturers and regulators have warned against some compounded GLP‑1 products.
• Variable pharmacy quality: only a very small number of compounding pharmacies meet high accreditation standards.

Better steps to try first

1. Appeal the insurance denial

   • Ask your prescriber to submit (or resubmit) a prior‑authorization appeal with a clear medical‑necessity letter that documents BMI, prior weight‑loss attempts, comorbidities (e.g., diabetes, sleep apnea, HTN), and why Wegovy is clinically indicated.
   • Ask the insurer for the exact reason for denial and whether a peer‑to‑peer review is possible.

2. Contact the drug manufacturer’s support/hub

   • Novo Nordisk (maker of Wegovy) has patient support and savings programs — contact their patient/hub services to ask about co‑pay cards (for commercially insured) or patient assistance programs if you’re uninsured/underinsured.
   • If tirzepatide (e.g., Zepbound/Mounjaro) is an option, contact Eli Lilly’s support teams for info on access programs.

3. Ask your clinician about alternatives

   • Approved alternatives for weight management: liraglutide (Saxenda), tirzepatide (Zepbound — if eligible), or off‑label use of semaglutide for diabetes (Ozempic) when clinically appropriate. Coverage and indications differ, so your prescriber can advise which might be more likely to be covered.
   • Consider nonpharmacologic options (structured medical weight‑management programs, nutrition/behavioral counseling, or bariatric surgery if you meet criteria).

4. Short‑term cost mitigation

   • Check GoodRx, Blink Health or RxSaver for cash‑price coupons for some GLP‑1s (more helpful for Ozempic/Rybelsus than Wegovy).
   • Ask your prescriber if a lower‑dose regimen or a different drug with better coverage is appropriate.

If you’re still considering compounded GLP‑1s

• Only consider them as a last resort and after discussing thoroughly with your clinician.
• If you do, insist on a compounding pharmacy with strong credentials (look for Pharmacy Compounding Accreditation Board (PCAB) accreditation and state board inspection records), and get written information about sterility testing, lot testing and COA (certificate of analysis).
• Understand you will pay out of pocket and that adverse events may be harder to trace or treat.

Practical next steps you can take today

• Call your insurer and get the denial reason and appeal instructions.
• Ask your prescriber to submit an appeal and request a peer‑to‑peer. Provide them with a short list of your weight history, comorbidities and prior treatments.
• Call Novo Nordisk’s patient support for Wegovy and ask about savings/assistance and temporary starter programs.
• If cost is the main barrier, ask your clinician whether an alternative GLP‑1 likely to be covered (or available cheaper via coupon) could be appropriate.

If you want, tell me:

• Whether you have commercial, Medicare, or Medicaid coverage, and
• Your clinical situation (BMI, diabetes or other conditions, prior treatments),

and I can draft a sample appeal letter/script for your prescriber and point you to the right manufacturer and discount resources.